CC
XERS icon

Centiva Capital’s Xeris Biopharma Holdings XERS Stock Holding History

Centiva Capital’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-39,086
Closed -$183K – 2041
2025
Q2 		$183K Sell
39,086
-22,967
-37% -$105K 0.01% 1356
2025
Q1 		$341K Buy
+62,053
New +$250K 0.02% 1015
2024
Q2 		– Sell
-33,589
Closed -$74.2K – 2582
2024
Q1 		$74.2K Sell
33,589
-8,779
-21% -$22.7K ﹤0.01% 1631
2023
Q4 		$99.6K Buy
+42,368
New +$78.2K 0.01% 1585
2021
Q2 		– Sell
-20,605
Closed -$93K – 1686
2021
Q1 		$93K Buy
+20,605
New +$111K 0.01% 1072

Other funds holding XERS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $244M AUM 80.12% 1-Year Est. Return